1. Home
  2. BW vs IPHA Comparison

BW vs IPHA Comparison

Compare BW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$6.28

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.70

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BW
IPHA
Founded
1867
1999
Country
United States
France
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
165.3M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
BW
IPHA
Price
$6.28
$1.70
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
★ $8.00
$5.75
AVG Volume (30 Days)
★ 4.2M
35.0K
Earning Date
05-11-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 41.46
N/A
EPS
N/A
★ N/A
Revenue
★ $1,062,388,000.00
N/A
Revenue This Year
$41.58
$180.36
Revenue Next Year
$66.70
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.70
$1.18
52 Week High
$22.03
$2.71

Technical Indicators

Market Signals
Indicator
BW
IPHA
Relative Strength Index (RSI) 36.31 34.75
Support Level $4.57 $1.67
Resistance Level $8.05 $1.83
Average True Range (ATR) 0.45 0.10
MACD 0.01 -0.03
Stochastic Oscillator 14.78 15.24

Price Performance

Historical Comparison
BW
IPHA

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: